Piramal Pharma declared their Q3 FY24 results on 30 Jan, 2024. The topline increased by 14.14% & the profit came at ₹10.11cr. It is noteworthy that Piramal Pharma had declared a loss of ₹90.18cr in the previous fiscal year same period. As compared to the previous quarter, the revenue grew by 2.47%.
The Selling, general & administrative expenses rose by 1.5% q-o-q & increased by 6.41% Y-o-Y.
The operating income was down by 3.17% q-o-q & increased by 16.65% Y-o-Y.
The EPS is ₹0.21 for Q3 FY24, which increased by 128.75% Y-o-Y.
Piramal Pharma has delivered -3.2% return in the last 1 week, 33.71% return in the last 6 months, and 0.11% YTD return.
Currently, Piramal Pharma has a market cap of ₹18319.52 Cr and a 52wk high/low of ₹148.7 & ₹61.62 respectively.
As of 01 Feb, 2024, out of 4 analysts covering the company, 4 analysts have given a Strong Buy rating.
The consensus recommendation as of 01 Feb, 2024, was to Strong Buy.
Piramal Pharma Financials
| Period | Q3 FY24 | Q2 FY24 | Q-o-Q Growth | Q3 FY23 | Y-o-Y Growth |
|---|
| Total Revenue | 1958.57 | 1911.38 | +2.47% | 1715.97 | +14.14% |
| Selling/ General/ Admin Expenses Total | 523.78 | 516.03 | +1.5% | 492.23 | +6.41% |
| Depreciation/ Amortization | 186.32 | 184.51 | +0.98% | 164.43 | +13.31% |
| Total Operating Expense | 1356.01 | 1289.08 | +5.19% | 1199.43 | +13.05% |
| Operating Income | 602.56 | 622.3 | -3.17% | 516.54 | +16.65% |
| Net Income Before Taxes | 19.36 | 39.56 | -51.06% | -73.64 | +126.29% |
| Net Income | 10.11 | 5.02 | +101.39% | -90.18 | +111.21% |
| Diluted Normalized EPS | 0.21 | 0.04 | +433.38% | -0.74 | +128.75% |
Stay updated on quarterly results with our
results calendar
